Prothena Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena or view top-rated stocks.

7 analysts have issued 1 year price objectives for Prothena's stock. Their PRTA stock forecasts range from $14.00 to $103.00. On average, they expect Prothena's share price to reach $71.00 in the next year. This suggests a possible upside of 155.7% from the stock's current price.
View analysts' price targets for Prothena or view top-rated stocks among Wall Street analysts.

Prothena's stock was trading at $49.40 at the start of the year. Since then, PRTA shares have decreased by 43.8% and is now trading at $27.77.
View the best growth stocks for 2022 here.

Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Prothena.

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.07. The biotechnology company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.23 million. Prothena had a net margin of 33.45% and a trailing twelve-month return on equity of 16.02%.
View Prothena's earnings history.

Some companies that are related to Prothena include Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Cytokinetics (CYTK), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Karuna Therapeutics (KRTX), Zai Lab (ZLAB) and Bausch Health Companies (BHC).
View all of PRTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.26%), State Street Corp (5.06%), First Light Asset Management LLC (3.93%), Palo Alto Investors LP (3.59%), Dimensional Fund Advisors LP (3.22%) and Vanguard Group Inc. (1.87%). Company insiders that own Prothena stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke and Wagner M Zago.
View institutional ownership trends for Prothena.

PRTA stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Citigroup Inc., Healthcare of Ontario Pension Plan Trust Fund, TD Asset Management Inc., Massachusetts Financial Services Co. MA, First Trust Advisors LP, Vanguard Group Inc., and Federated Hermes Inc.. Company insiders that have sold Prothena company stock in the last two years include Carol D Karp, Christopher S Henney, Dennis J Selkoe, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke, and Wagner M Zago.
View insider buying and selling activity for Prothena or view top insider-selling stocks.

PRTA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Paradigm Biocapital Advisors LP, First Light Asset Management LLC, Sessa Capital IM L.P., Renaissance Technologies LLC, Prosight Management LP, Capital Fund Management S.A., and Mariner LLC.
View insider buying and selling activity for Prothena or or view top insider-buying stocks.

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTA stock can currently be purchased for approximately $27.77.

Prothena (NASDAQ:PRTA) has a market capitalization of $1.30 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or $1.22 on an earnings per share basis.

Prothena employs 82 workers across the globe.

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for Prothena is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at [email protected], or via fax at 353-1902-3510.